Gary M. Phillips
Independent Chairman of Supervisory boardDr. Gary M. Phillips, M.D., MBA is Director of Rheon Medical SA. He is Chairman of the Supervisory Board at Bioconnection B.V. from August 2024. He had been President and Chief Executive Officer of OrphoMed, Inc. since March 2018 and serves as its Director since May 2009. He has been Chairman of Supervisory Board at Nanobiotix S.A. since May 2021. He was Chief Business Officer at Anaveon AG since May 2022. He had been Independent Director of Zyla Life Sciences (formerly known as Egalet Corporation) since June 2018. He has served as President and Chief Executive Officer at OrphoMed, Inc. since April 2018 and has been its Director since May 2009. He was Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc from October 2013 to March 2018. He served as the Executive Vice President of Mallinckrodt public limited company an served as its Chief Strategy Officer since January 07, 2015 until 2018. He served as the Senior Vice President and President of Autoimmune & Rare Disease Business at Mallinckrodt Public Limited Company since August 2014 until January 2015. He served as the Head of U.S. Pharmaceutical & Surgical Businesses of Bausch & Lomb Incorporated since January 1, 2007. He served as Vice President of Global Pharmaceutical & Vitreoretinal Products of Bausch & Lomb Incorporated since October 2002. He has also held executive roles at Merck Serono, Merck KGaA, Novartis and Wyeth (now Pfizer) and served as a healthcare strategy management consultant at Towers Perrin (now Towers Watson) and as a Medical Officer with the United States Navy from which he was honorably discharged as a lieutenant commander. He served as the President of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior) from 2011 to 2012 and held the dual roles of President, U.S. Surgical and Pharmaceuticals at Bausch & Lomb Incorporated from 2007 to 2008 and also served as its Global Head of Pharmaceuticals. He served as Corporate Vice President of Bausch & Lomb Incorporated from January 2007 to 2008. He served as Vice President of Commercial Operations, US Pharmaceutical & Surgical Businesses of Bausch & Lomb Incorporated from January 5, 2007 to January 2008. He served as the Head of Operations of Greece, Italy, South Africa and Turkey and Vice President of Bausch & Lomb Incorporated. He served as an Executive Director of Strategic Planning at Novartis Pharmaceuticals from 2000 to 2002. He served as Director of Portfolio Management and Strategic Planning, Wyeth-Ayerst Pharmaceuticals from 1999 to 2000. He served as Managing Consultant for Pharmaceutical Strategy Practice at Towers Perrin (now Willis Towers Watson) from 1997 to 1999. He has also held positions of leadership at Novartis Pharmaceuticals, Wyeth-Ayerst Pharmaceuticals and Gensia Pharmaceuticals. He served as Vice President of Portfolio Management, Innovation & Business Intelligence at Merck Serono from 2008 to 2011. He has more than 20 years' experience in strategy, business development and licensing, commercial operations, business analytics and clinical medicine in the pharmaceutical and healthcare industries. He served as an Executive Chairman of Envisia Therapeutics Inc. until December 8, 2015. He has been Independent Director of Aldeyra Therapeutics, Inc. since May 2009. He has been an Independent Director at Inotek Pharmaceuticals Corporation since October 13, 2015. He has been a Director of Envisia Therapeutics Inc. since July 30, 2014. Before joining Mallinckrodt, he served as the Head of Global Health and Healthcare Industries at the World Economic Forum in Geneva, Switzerland from January 2012 to September 2013. He serves as a Member of the Board of Directors at Wilson Commencement Park in Rochester and the YMCA of Greater Rochester. He also served four years in the United States Navy as an emergency and primary care physician. He is a Member of the University of Pennsylvania's Medical Alumni Leadership Council. He maintains an active medical license. r. Phillips attended the University of Pennsylvania, where he earned a Medical Degree (Alpha Omega Alpha) from the School of Medicine in 1992, an MBA in Health Care Management from the Wharton School in 1991 and a B.A. (summa cum laude, Phi Beta Kappa) in Biochemistry from the College of Arts and Sciences in 1987. He completed his Postgraduate Medical Education at Naval Medical Center San Diego.
Positions
- Company NameNanobiotix S.A.Stock CodeNBTXPositionIndependent Chairman of Supervisory boardColleagues
- LLLaurent LevyCo-Founder, President of the Executive Board & CEO
- GMGary M. PhillipsIndependent Chairman of Supervisory board
- AHAnne-Juliette HermantChief People Officer & Member of Executive Board
- LKLouis KayitalireChief Medical Officer & Member of Executive Board
- EJEarl J. BergeyCo-Founder
- ACArnd ChristCFO & Member of Executive Board
- AGAnne-Marie GraffinIndependent Vice Chairwoman of the Supervisory Board
- LALeonard A. FarberChief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board
- ESEnno SpillnerIndependent Member of Supervisory Board
- AHAlain HerreraIndependent Member of Supervisory Board
- Company NameAldeyra Therapeutics, Inc.Stock CodeALDXPositionIndependent DirectorColleagues
- TCTodd C. BradyCEO, President & Director
- RHRichard Huntington DouglasIndependent Chair of the Board
- MAMichael AlfieriHead of Finance and Principal Financial & Accounting Officer
- DBDavid BurkeHead of Investor Relations
- ALAdam LazorchakDirector of Translational Sciences & Non-Clinical Development
- BRBen R. BronsteinIndependent Director
- DMDarlene M. Deptula-HicksIndependent Director
